Redifferentiation Effect of Larotrectinib for NTRK Fusion-Positive Pediatric Thyroid Cancer and Outcomes After Therapy
Open Access
- 5 June 2025
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 9 (8)
Abstract
Context: Few data exist regarding larotrectinib therapy in pediatric NTRK fusion–positive papillary thyroid cancer (PTC), especially its effects on redifferentiation in radioactive iodine–refractory (RAIR) disease. Objective: To describe redifferentiation effects and disease outcomes in patients with stage 2 pediatric PTC following treatment with larotrectinib ± RAI. Methods: A retrospective case series at a tertiary cancer center of patients with NTRK fusion–positive pediatric PTC and RAIR pulmonary metastases treated with larotrectinib and considered for 131I therapy. Tumor response was assessed utilizing RECIST 1.1. Results: Four patients (aged 6-16 years at PTC diagnosis; 50% female) were treated with larotrectinib 100 mg twice a day for a median of 14 months (range 6-30 months). Treatment was well tolerated, except for grade 3 hypocalcemia in 1 patient with pre-existing hypoparathyroidism. All patients had tumor shrinkage (−25% to −100%) in target and nontarget pulmonary metastases. On diagnostic 123I thyroid scans, any RAI uptake was identified in only 2 patients, and therapeutic 131I did not cause further incremental tumor shrinkage in the patients treated, despite robust pulmonary uptake on the post-therapy scans. After stopping larotrectinib and with a mean follow-up of 38 months (range 26-48 months), 2 patients had stable disease and 2 had clinically insignificant tumor progression. Conclusion: Although larotrectinib can have a redifferentiation effect in pediatric NTRK fusion-positive PTC, therapy with 131I may not lead to an incremental benefit in established RAIR disease. Significant structural disease progression did not occur after cessation of larotrectinib, suggesting that a drug holiday can safely be considered in this population.Keywords
This publication has 23 references indexed in Scilit:
- Lung Metastasis in Children with Differentiated Thyroid Cancer: Factors Associated with Diagnosis and Outcomes of TherapyThyroid®, 2021
- Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and OutcomeThe Journal of Clinical Endocrinology & Metabolism, 2018
- Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersThe Journal of Clinical Endocrinology & Metabolism, 2018
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineThe Journal of Clinical Endocrinology & Metabolism, 2018
- Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long‐Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015)World Journal of Surgery, 2017
- Biologic and Clinical Perspectives on Thyroid CancerNew England Journal of Medicine, 2016
- Uncommon TERT Promoter Mutations in Pediatric Thyroid CancerThyroid®, 2016
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with DabrafenibClinical Cancer Research, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009